Item Type: | Article |
---|---|
Title: | Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma |
Creators Name: | Weisel, K.C., Weidmann, E., Anagnostopoulos, I., Kanz, L., Pezzutto, A. and Subklewe, M. |
Abstract: | Epstein-Barr virus (EBV)-associated B-cell lymphoproliferative disorders occur at an increasing frequency in various hereditary and acquired states of immune dysfunction. In a few cases of T-cell lymphoma, especially in angioimmunoblastic T-cell lymphoma (AILT), EBV-associated B-cell lymphoproliferative disorders have been reported. Here, we present two cases of EBV-associated B-cell lymphoma after treatment of T-cell lymphoma (AILT and peripheral T-cell lymphoma, unspecified, PTCL-NOS) with a regimen containing alemtuzumab and fludarabine. Conventional and immunohistological tissue staining showed the typical features of highly proliferating diffuse large B-cell lymphoma in both cases. The monoclonal B-cell population displayed EBV latency type III. At the time of diagnosis the cellular immune status of both patients was severely compromised with an absolute CD4 T-cell count below <120 mul(-1). Our observation supports the notion that combination of cytotoxic drugs and immunosuppressive antibodies in patients with T-cell lymphoma may severely aggravate the already present immunodeficiency. We suggest to monitor the cellular immune status in combination with the EBV load in high risk patients for early detection-and possibly intervention-of EBV-associated lymphoma. |
Keywords: | Epstein–Barr Virus, Secondary B-Cell Lymphoma, Peripheral T-Cell Lymphoma, AILT, Alemtuzumab, Fludarabine |
Source: | International Journal of Hematology |
ISSN: | 0925-5710 |
Publisher: | Springer |
Volume: | 88 |
Number: | 4 |
Page Range: | 434-440 |
Date: | November 2008 |
Official Publication: | https://doi.org/10.1007/s12185-008-0176-2 |
PubMed: | View item in PubMed |
Repository Staff Only: item control page